Oventus Medical Ltd (ASX:OVN) are pleased to provide the Company's latest Investor Update. Oventus have achieved a number of significant milestones in the last quarter, expanding the commercialisation efforts of our O2Vent(TM) T device in numerous geographical regions and strengthening our sales and operational systems.
An oral drench to protect piglets from gut infection could soon be available to pig farmers. It's been developed by scientists and is made from pineapples - taking antibiotics out of the food chain.
Rhinomed (ASX:RNO) advises it has undertaken a AUD$2.19 million private placement to two US based sophisticated investor groups as part of its 15% placement capacity. In addition, the company has flagged its intention to hold a General Meeting to approve a capital management initiative that will seek to consolidate the company's capital and provide a sale of less than marketable share parcels facility.
With the recent announcement of a significant licensing deal with AGC Ltd in Japan, the company is set to build on their platform for the delivery of Progenza to deal with many healthcare issues from arthritis and pain, to genetic disorders.
Rhinomed (ASX:RNO) is pleased to provide an update on the expansion of its global distribution program. The company can report that Rhinomed has been added as a vendor by two major US based pharmacy wholesalers and the successful expansion of the listing of its Mute Sleep technology by Symbion in Australia.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide the Company's Half Yearly Report for the period ended 31 December, 2016.
Immuron Limited (ASX:IMC) (OTCMKTS:IMROY) wishes to advise investors that European and US-based Life Sciences Research and Analyst firm Van Leeuwenhoeck Institute, has published an updated in-depth Research Report on the Company and its R&D programs.
